GlassScriptPhysician profile
Tanis Bast
NPI 1295193274
$38,385.91
in general payments reported to CMS, 2019-2025
40 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,700 · 2022: $1,051 · 2023: $1,622 · 2024: $1,587 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $6,909 · Honoraria: $5,963 · Travel and Lodging: $5,343 · Consulting Fee: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,860.00 |
| Food and Beverage | $6,909.03 |
| Honoraria | $5,962.50 |
| Travel and Lodging | $5,343.24 |
| Consulting Fee | $560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21,539.36 | 2022-2025 | Vivitrol, Aristada, Vivitrol |
| Braeburn INC. | $9,740.55 | 2023-2025 | Brixadi |
| Abbvie INC. | $1,150.93 | 2021-2025 | |
| Indivior INC. | $1,148.96 | 2021-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $537.62 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.06 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $422.71 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $334.46 | 2021-2024 | Wegovy |
| Glaxosmithkline, LLC. | $327.78 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.66 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.27 | 2021-2023 | Stiolto Respimat, Jardiance |
| Astrazeneca Pharmaceuticals LP | $243.80 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $222.31 | 2021-2022 | |
| Axsome Therapeutics, INC. | $215.91 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $203.60 | 2021-2025 | Austedo Xr, Uzedy, Ajovy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanis Bast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.